sarpogrelate has been researched along with 3-(3-(dimethylamino)propyl)-4-hydroxy-n-(4-(4-pyridinyl)phenyl)benzamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Itoh, T; Kajikuri, J; Kodama, A; Komori, K | 1 |
1 other study(ies) available for sarpogrelate and 3-(3-(dimethylamino)propyl)-4-hydroxy-n-(4-(4-pyridinyl)phenyl)benzamide
| Article | Year |
|---|---|
Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts.
Topics: Animals; Benzamides; Carotid Artery, Common; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Graft Occlusion, Vascular; Jugular Veins; Male; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Pyridines; Rabbits; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Vasoconstriction | 2009 |